About
Kestrel Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors targeting KRAS mutations to treat multiple types of KRAS-driven cancers.
Explore Kestrel Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.